BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//wp-events-plugin.com//7.2.3.1//EN
BEGIN:VEVENT
UID:2@myasthenia.org
DTSTART;TZID=America/New_York:20240620T220000
DTEND;TZID=America/New_York:20240620T233000
DTSTAMP:20241028T210324Z
URL:https://myasthenia.org/events/research-webinar-argenx-clinical-trial-u
 pdate-adapt-seron-2024-06-20/
SUMMARY:Research Webinar: argenx Clinical Trial Update – Adapt Seron
DESCRIPTION:argenx Clinical Trial Update &ndash\; Adapt Seron Thursday\, Ju
 ne 20 3:00 PM EST / 12:00 PM PDT Presented by: Jeffrey T. Guptill\, MD\, M
 A\, MHS  Register   Session Description: Adapt seron is a phase 3 study to
  evaluate the efficacy of safety of Efgartigimod IV in patients with AChr 
 &ndash\; gMG\, including MuSK-Ab\, LRP4-Ab\, and gMG patients with no iden
 tifiable autoantibodies.  About the Presenter: Dr. Jeffrey Guptill is Neur
 omuscular Franchise Lead in Clinical Development at argenx. In this role h
 e oversees the late-stage clinical development programs for efgartigimod (
 FcRn inhibitor) and empasibrupart (C2 complement inhibitor). He is also Ad
 junct Associate Professor of Neurology at Duke University School of Medici
 ne. Dr. Guptill received his medical training at Virginia Commonwealth Uni
 versity and subsequently completed an adult neurology residency and neurom
 uscular medicine/EMG and advanced neuromuscular disease fellowships at Duk
 e University. Prior to joining argenx\, he was a tenured Associate Profess
 or of Neurology at Duke University.   
ATTACH;FMTTYPE=image/jpeg:https://myasthenia.org/wp-content/uploads/Portal
 s/0/EasyDNNNews/764/jeff-g-webinarjune20-header1-2.jpg
CATEGORIES:Events,Webinars
END:VEVENT
BEGIN:VTIMEZONE
TZID:America/New_York
X-LIC-LOCATION:America/New_York
BEGIN:DAYLIGHT
DTSTART:20240310T030000
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
END:DAYLIGHT
END:VTIMEZONE
END:VCALENDAR